Recombinant Human EPO
Catalog No : IGX-RP236
169.75€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Recombinant Human EPO | ||
|---|---|---|---|
| Catalog No | IGX-RP236 | ||
| Supplier’s Catalog No | IGX-RP236 | ||
| Supplier | ImuGeX | ||
| Source antigen | HEK293 | ||
| Reactivity | Human | ||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 20 | ||
| Storage | -70°C | ||
|---|---|---|---|
| Other names | Erythropoietin<br/>Recombinant Human Erythropoietin-Alpha (EPO) | ||
| Grade | Highly Purified | ||
| Purity | >95% as determined by SDS-PAGE | ||
| Form | Lyophilized from a 0.2 μm filtered solution in PBS (pH 7) | ||
| Reactivity life | 6 months | ||
| Note | For reserch purpose only | ||
| Purity | >95% as determined by SDS-PAGE | ||
| Description | EPO is predominantly synthesized and secreted by tubular and juxtatubular capillary, endothelial, and interstitial cells of the kidney. Approximately 10-15% of the total amount of EPO comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of EPO is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behaviour of EPO in vivo. Non-glycosylated Epo has an extremely short biological half life. Recombinant Human EPO is a glycosylated protein that runs at approximately 35 kDa owing to its glycosylation. | ||
Product Details
© 2020 Imugex All Rights Reserved